BIOGEN INC (BIIB) Fundamental Analysis & Valuation

NASDAQ:BIIB • US09062X1037

Current stock price

183.94 USD
+0.3 (+0.16%)
At close:
184 USD
+0.06 (+0.03%)
After Hours:

This BIIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BIIB Profitability Analysis

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • In the past year BIIB had a positive cash flow from operations.
  • In the past 5 years BIIB has always been profitable.
  • Each year in the past 5 years BIIB had a positive operating cash flow.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • With an excellent Return On Assets value of 4.39%, BIIB belongs to the best of the industry, outperforming 90.17% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 7.08%, BIIB belongs to the top of the industry, outperforming 91.14% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 8.93%, BIIB belongs to the top of the industry, outperforming 92.87% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.95%.
  • The last Return On Invested Capital (8.93%) for BIIB is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • BIIB has a Profit Margin of 13.07%. This is amongst the best in the industry. BIIB outperforms 91.91% of its industry peers.
  • BIIB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.94%, BIIB belongs to the top of the industry, outperforming 95.76% of the companies in the same industry.
  • BIIB's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BIIB (75.69%) is better than 83.62% of its industry peers.
  • BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BIIB Health Analysis

2.1 Basic Checks

  • BIIB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, BIIB has more shares outstanding
  • Compared to 5 years ago, BIIB has less shares outstanding
  • The debt/assets ratio for BIIB has been reduced compared to a year ago.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • BIIB has an Altman-Z score of 3.30. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BIIB (3.30) is better than 69.56% of its industry peers.
  • The Debt to FCF ratio of BIIB is 3.11, which is a good value as it means it would take BIIB, 3.11 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BIIB (3.11) is better than 92.68% of its industry peers.
  • BIIB has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • BIIB's Debt to Equity ratio of 0.34 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.3
ROIC/WACC0.99
WACC8.99%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.68. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.68, BIIB is doing worse than 68.02% of the companies in the same industry.
  • BIIB has a Quick Ratio of 2.03. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.03, BIIB is doing worse than 74.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. BIIB Growth Analysis

3.1 Past

  • The earnings per share for BIIB have decreased by -7.16% in the last year.
  • Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.17% on average per year.
  • Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 2.22% in the last year.
  • BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 3.53% on average per year.
  • The Revenue is expected to decrease by -0.48% on average over the next years.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.94%
Revenue Next 2Y-2.41%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. BIIB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 12.03, which indicates a correct valuation of BIIB.
  • Based on the Price/Earnings ratio, BIIB is valued cheaper than 96.34% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.50, BIIB is valued rather cheaply.
  • The Price/Forward Earnings ratio is 11.44, which indicates a very decent valuation of BIIB.
  • Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 97.50% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.67. BIIB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 12.03
Fwd PE 11.44
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 96.92% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
  • BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 96.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.37
EV/EBITDA 8.09
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.33
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIIB Dividend Analysis

5.1 Amount

  • No dividends for BIIB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIIB Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

NASDAQ:BIIB (3/24/2026, 8:15:47 PM)

After market: 184 +0.06 (+0.03%)

183.94

+0.3 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner Change5.37%
Ins Owners0.16%
Ins Owner Change7.93%
Market Cap27.00B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target210.39 (14.38%)
Short Float %2.88%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)7.72%
PT rev (3m)15.94%
EPS NQ rev (1m)0.87%
EPS NQ rev (3m)-13.21%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)-0.82%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.43%
Valuation
Industry RankSector Rank
PE 12.03
Fwd PE 11.44
P/S 2.73
P/FCF 13.37
P/OCF 12.24
P/B 1.48
P/tB 10.43
EV/EBITDA 8.09
EPS(TTM)15.29
EY8.31%
EPS(NY)16.08
Fwd EY8.74%
FCF(TTM)13.76
FCFY7.48%
OCF(TTM)15.02
OCFY8.17%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)2.33
PEG (5Y)N/A
Graham Number206.87
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.3
F-Score4
WACC8.99%
ROIC/WACC0.99
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.94%
Revenue Next 2Y-2.41%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 6 / 10.